BIO attacks US proposal from HHS advisory panel for gene patent limits
This article was originally published in Scrip
Executive Summary
A US federal advisory panel has released six recommendations concerning gene patents. Most significantly, the panel advises that Congress exempt gene patents from infringement liability in certain areas, specifically by limiting the ability of holders of gene patents to keep others from using those genes for diagnostic tests or for research purposes – a move that has drawn ire from some in the industry, including the USBiotechnology Industry Organization (BIO). The recommendations, if implemented, would unravel two sets of laws that are the foundation of science innovation in the US, BIO asserts.